Public screening for COVID-19 in Wuhan, China and beware of the antibody positive in women and tumor patients.
Yufeng ShangYuxing LiangTao LiuJingfeng LiFuling ZhouPublished in: Journal of medical virology (2021)
The novel coronavirus disease 2019 (COVID-19) has become a global health emergency. Early detection and intervention are key factors for improving outcomes in patients with COVID-19. Real-time reverse transcriptase polymerase chain reaction-based molecular assays and antibody for detecting SARS-CoV-2 in respiratory specimens are the current reference standard for COVID-19 diagnosis. Clinical implications of different specimen types for nucleic acid and antibody testing of COVID-19 in Zhongnan hospital of Wuhan University were analyzed. Compared with health groups, tumor patients had higher rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (+/-) immunoglobulin M (IgM) (+) immunoglobulin G (IgG) (+). The rate of SARS-CoV-2 (-) IgM (+) IgG (-) or SARS-CoV-2 (-) IgM (-) IgG (+) in female was significantly higher than that in male. These results can help governments to take screening measures to prevent the COVID-19 pandemic again.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- healthcare
- public health
- ejection fraction
- global health
- chronic kidney disease
- newly diagnosed
- randomized controlled trial
- nucleic acid
- peritoneal dialysis
- prognostic factors
- mental health
- emergency department
- pregnant women
- high throughput
- patient reported outcomes
- skeletal muscle
- metabolic syndrome
- polycystic ovary syndrome
- social media
- risk assessment
- health information
- adverse drug